
ASCO highlight aspirin’s role in reducing hereditary cancer risk.
The American Society of Clinical Oncology (ASCO), in their 16th Annual Report on Progress Against Cancer – Clinical Cancer Advances 2021, highlight the preventative role
ASCO highlight aspirin’s role in reducing hereditary cancer risk.
Founded in 1974, the International Aspirin Foundation shares information and stimulates research interest and discussion about all aspects of aspirin and acetylsalicylic acid.
Scientific Advisory Board
Key Features
Scientific Conference
The American Society of Clinical Oncology (ASCO), in their 16th Annual Report on Progress Against Cancer – Clinical Cancer Advances 2021, highlight the preventative role
Contributions from the research community shared here are unsolicited and are not peer reviewed. We encourage sharing information and stimulating research interest, but we do not endorse or approve the submission. See full disclaimer
Professor Mazzeffi.
This virtual event celebrated the work of Professors Lars Wallentin, Bo Norrving, Jan van Gijn and Tom Meade, the scientists who led four pivotal low-dose aspirin trials, which ultimately contributed to the prevention of countless coronary and cardiovascular events worldwide.
Prof Wallentin gave a presentation on low dose aspirin in acute coronary syndrome, and the findings of the RISC research group. The influence of this work was put into context with a 2020 review that showed the recent pharmacology interventions in acute coronary syndromes.
Have something to say about aspirin?
We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.
Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.
Medical Oncology
In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.
I received grant support for investigator-initiated research from:
I hold shares in: Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics
I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.
Junbo Ge
Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.
Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.
AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award
Click here to find the press release.
I received consultant Bayer and Pfizer, Inc.
I received grant support for investigator-initiated research from:
Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
Discipline: Cardiology and Epidemiology
I received consultant and speaker fees Bayer.
I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.
Peter M. Rothwell PhD, MD, FRCP, FMedSci
I received consultant and speakers fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, Tremeau, Zambon.
I received grant support for investigator-initiated research from: